Skip to main content
. 2024 Jul 3;43(32):2475–2489. doi: 10.1038/s41388-024-03094-1

Fig. 1. SLFN11 enhances cellular sensitivity to PARP inhibitors in BRCA1/2-deficient cells.

Fig. 1

A Immunoblots of whole cell lysates from genetically modified TOV-112D cells: SLFN11-proficient (parent), SLFN11-KO, control siRNA (siCON) or BRCA2 siRNA (siBRCA2). Blots were probed with the indicated antibodies. B, C Viability of TOV-112D cells under each condition after 48 h of continuous drug treatment. Cellular ATP activity was used to measure cell viability. The viability of untreated cells was set as 100%. Data are means ± standard deviations (n = 3, technical replicates) and represent one of two independent experiments. D Apoptosis analysis of TOV-112D cells by flow cytometry. The indicated cell lines were treated continuously with 2.5 μM olaparib for 0, 24, or 48 h. Data represents one of two independent experiments. E Immunoblots showing BRCA1 knockdown by siRNA for BRCA1. Data are shown as in A. F Cell proliferation curves of the indicated TOV-112D cells. G Viability of TOV-112D cells under the indicated conditions after 48 and 72 h of continuous olaparib treatment. NS not significant, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (one-way analysis of variance with Tukey’s post-hoc multiple comparisons test).